Target
Vincristine
27 abstracts
Abstract
Survival outcomes associated with first-line PCV or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma.Org: Paris Brain Institute (ICM), Service de Neurologie 2 Mazarin, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, AP-HP, Sorbonne Université, Lyon HCL,
Abstract
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,
Abstract
Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.Org: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital),
Abstract
Phase I dose escalation and pharmacokinetics clinical trial of mitoxantrone hydrochloride liposome in children with relapsed and refractory solid tumors.Org: Wuhan Children's Hospital,
Abstract
EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma.Org: Manchester Cancer Research Centre, Sir Peter MacCallum Cancer Centre Melbourne, University of Modena and Reggio Emilia,
Abstract
Rituximab, chidamide, and zanubrutinib (ZCR) ± CHOP as a regimen for treatment naive (TN) double-expressor DLBCL (DE-DLBCL).Org: Affiliated Dongguan People’s Hospital, Dongguan People’s Hospital,
Abstract
Efficacy and safety of mosunetuzumab-based regimens as first-line therapy in non-Hodgkin lymphomas: A systematic review of clinical trials.Org: New York Medical College at St.Michael's, New York Medical College at St. Michael’s Medical Center,
Abstract
Association of elevated ctDNA burden following one cycle of chemotherapy with inferior outcomes for patients with metastatic Ewing sarcoma: A report from the Children’s Oncology Group (COG).Org: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Children's Oncology Group Statistics and Data Center, University of Florida, Broad Institute of MIT and Harvard, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Memorial Sloan Kettering Cancer Center,
Abstract
Effect of AVM0703 treatment on the limitations of R-CHOP and survival in a model applicable to ABC subtype DLBCL.Org: AVM Biotechnology,
Abstract
Effect of 1-L-MT on immunotherapy of diffuse large B-cell lymphoma via downregulation of PD-L1.Org: Shandong Provincial Qianfoshan Hospital,
Abstract
A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma.Org: National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, Nagoya City University Graduate School of Medical Sciences, Imamura General Hospital, Kumamoto University Hospital, Kindai University Faculty of Medicine, Osaka-Sayama, Japan,
Abstract
Treatment of focal anaplastic Wilms tumor (FAWT): A report from the Children’s Oncology Group (COG) AREN0321 and AREN03B2 studies.Org: Washington University in St Louis, University of Southern California, Los Angeles, CA, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Michigan Hospital, Uniformed Services University of the Health Sciences,
Abstract
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.Org: Levine Cancer Institute, Wilmot Cancer Institute, BC Cancer Centre for Lymphoid Cancer, Willamette Valley Cancer Institute and Research Center, US Oncology Research,
Abstract
Evaluation of outcomes between rituximab-abbs and reference product rituximab in adult patients with newly diagnosed diffuse large B-cell lymphoma in a non-inferiority study.Org: Kaiser Permanente Oakland Medical Center, Kaiser Permanante, Kaiser Permanente Davis, Kaiser Permanante Irvine, Kaiser Permanente Pasadena,
Abstract
Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.Org: Lymphoma Service, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Vejle Hospital, Universitair Ziekenhuis Gent, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.Org: IRCCS Ospedale Pediatrico Bambino Gesu, University College London Hospitals NHS Foundation Trust, Hospital Universitari Vall d Hebron, Regina Margherita Childrens Hospital and University of Turin, Turin, Italy, Princess Máxima Centrum,
Abstract
Physical and emotional quality of life in children with B-acute lymphoblastic leukemia randomized to every 4- vs. 12-week vincristine/dexamethasone during maintenance: Children’s Oncology Group AALL0932.Org: Children's Oncology Group Data Center, Yale University Hematology/Oncology, St. Jude Children's Research Hospital, Children's National Medical Center, Washington, DC, University of Texas Southwestern Medical Center,
Abstract
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, Seagen, Inc.,
Abstract
Immunomodulatory AVM0703 enhances R-CHOP anti-lymphoma effect with reduced toxicity: Immune-resistant, aggressive A20 lymphoma model.Org: AVM Biotechnology, Inc., AVM Biotechnology,
Abstract
Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).Org: Institut Curie, Saint Cloud, France, Institut Curie, Biostatistics Unit, Centre Henri-Becquerel and University of Rouen, Bergonié Institute, Neurology, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière,
Abstract
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.Org: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, Dana-Farber Cancer Institute, Boston, MA, USA, Moffitt Cancer Center and Research Institute, Tampa, FL, Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain, University of Lille, Centre Hospitalier Universitaire, Lille, France,
Abstract
Association of COVID-19 pandemic with indolent lymphoma care delivery and outcomes in Ontario, Canada: A population-based analysis.Org: Princess Margaret Cancer Centre, University Health Network, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Toronto, Institute for Clinical Evaluative Sciences,
Abstract
Pelvic Ewing sarcoma in children: Multimodal treatment, long term outcome and prognostic factors.Org: Istanbul University School of Medicine, Oncology Institute of Southern Switzerland, Pediatric Hematology-Oncology, Radiation Oncology Division, Istanbul Medical Faculty,
Abstract
Real-world efficacy of chemotherapy in patients with advanced extramammary Paget's disease: A retrospective, multicenter study of 204 Japanese patients.Org: Kumamoto University Hospital, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Nagoya City University Graduate School of Medical Sciences, National Cancer Center Hospital East, Kashiwa, Japan, Graduate School of Medicine, Chiba University,
Abstract
Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Presentation of congenital soft-tissue sarcomas: A single institution experience.Org: Nicklaus Children's Hospital, Nicklaus Children's Hospital Department of Pathology,
Abstract
Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): A phase II study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,